

Tozinameran

S

Hepatitis, colitis and myalgia: 2 case reports

In an observational, longitudinal, multicenter study of 82 patients enrolled between 24 March 2021 and 23 April 2021, 2 patients including one woman [*ages and not all sexes stated*] were described, who developed hepatitis, colitis and myalgia following first dose of vaccination with tozinameran against COVID-19.

The patient who was diagnosed with cancer was treated with unspecified immune checkpoint inhibitor. Then the patient, enrolled into the study and received the first dose of tozinameran [BNT162b2 vaccine] vaccine [*route and dosage not stated*]. However, the patient developed myalgia that was attributed to tozinameran vaccination [*time to reaction onset not stated*].

Lasagna A, et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open 6: No. 5, Oct 2021. Available from: URL: <https://www.journals.elsevier.com/esmo-open/> 803661141

» **Editorial comment:** Details of this case report have previously been published and processed for Adis PV [see Reactions 9999; 803621724]. The woman had developed grade 3 hepatitis and required hospitalisation.